AGIOS PHARMACEUTICALS, INC.AGIO
| Dec 31,
2013 | Dec 31,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net income (loss) | -39 | -54 | -118 | -198 | -315 | -346 | -411 | -327 | 1,605 | -232 | -352 | 674 |
|---|
| Depreciation and amortization | - | - | - | - | - | - | - | 10 | 9 | 9 | 7 | 6 |
|---|
| Stock-based compensation expense | 3 | 12 | 32 | 42 | 48 | 73 | 72 | 75 | 54 | 49 | 45 | 43 |
|---|
| Net accretion of discount on marketable securities | -0 | -1 | -1 | -1 | 0 | 4 | 3 | -3 | -7 | 1 | 5 | 14 |
|---|
| Gain on sale of contingent payments | - | - | - | - | - | - | - | - | - | 128 | - | 889 |
|---|
| Loss (gain) on disposal of property and equipment | - | - | - | - | - | - | - | - | -0 | 0 | -1 | 0 |
|---|
| Non-cash operating lease expense | - | - | - | - | - | - | - | 9 | 10 | 10 | 11 | 12 |
|---|
| Expense associated with license agreement | - | - | - | - | - | - | - | - | - | - | 18 | - |
|---|
| Realized gain on investments | - | - | - | - | - | - | - | - | - | - | 0 | 0 |
|---|
| Milestone payment from gain on sale of oncology business | - | - | - | - | - | - | - | - | 7 | - | - | 200 |
|---|
| Accounts receivable, net | - | - | - | - | - | - | - | - | - | 2 | 1 | 1 |
|---|
| Inventory | - | - | - | - | - | 1 | 6 | 7 | - | 8 | 11 | 9 |
|---|
| Other receivables | - | - | - | - | - | 5 | 4 | 12 | 4 | -0 | - | - |
|---|
| Prepaid expenses and other current and non-current assets | 2 | 3 | 4 | 3 | 7 | -1 | 8 | 1 | 27 | 0 | -4 | 6 |
|---|
| Accounts payable | 0 | 8 | 4 | 4 | 5 | -5 | 4 | 6 | 2 | 3 | -9 | 7 |
|---|
| Accrued expenses | 5 | 5 | 2 | 17 | 2 | 9 | 7 | 11 | 0 | -2 | 13 | 4 |
|---|
| Income taxes payable | -3 | -5 | 4 | - | - | - | - | - | - | - | - | 1 |
|---|
| Operating lease liabilities | - | - | - | - | - | - | -7 | -8 | -8 | -11 | -14 | -15 |
|---|
| Other liabilities | - | - | - | - | - | - | - | - | - | 3 | -2 | -0 |
|---|
| Net cash used in operating activities | -56 | - | - | - | -285 | -304 | -371 | -291 | -407 | -309 | -296 | -390 |
|---|
| Purchases of marketable securities | - | - | - | - | - | - | 489 | 557 | 1,378 | 1,031 | 418 | 1,542 |
|---|
| Proceeds from maturities and sales of marketable securities | 60 | 506 | 502 | 397 | 635 | 666 | 592 | 648 | 830 | 1,146 | 675 | 818 |
|---|
| Proceeds from sale of contingent payments | - | - | - | - | - | - | - | - | - | 132 | - | 889 |
|---|
| Proceeds from Divestiture of Businesses | - | - | - | - | - | - | - | - | - | - | - | 200 |
|---|
| Payments associated with license agreement | - | - | - | - | - | - | - | - | - | - | 18 | - |
|---|
| Purchases of property and equipment | 1 | 2 | 20 | 10 | 5 | 7 | 12 | 15 | 6 | 5 | 1 | 2 |
|---|
| Proceeds from sale of equipment | - | - | - | - | - | - | - | - | - | 1 | 1 | 0 |
|---|
| Net cash provided by investing activities | -87 | - | - | - | -58 | -274 | 91 | 76 | 1,249 | 243 | 240 | 363 |
|---|
| Payments on financing lease obligations | - | - | - | - | - | - | 0 | 0 | 1 | 0 | - | - |
|---|
| Net proceeds from stock option exercises and employee stock purchase plan | - | - | - | - | 14 | 30 | 13 | 11 | 37 | 3 | 5 | 14 |
|---|
| Net cash provided by financing activities | 124 | - | - | - | 285 | 546 | 290 | 262 | -766 | 2 | 5 | 14 |
|---|
| Net change in cash and cash equivalents | - | - | - | - | - | - | 10 | 47 | 76 | -64 | -51 | -12 |
|---|
| Capital Expenditures Incurred but Not yet Paid | 0 | 2 | 2 | 0 | 1 | 1 | 5 | 0 | 2 | 0 | 0 | 0 |
|---|
| Income Taxes Paid | - | 6 | - | - | - | - | - | - | 16 | - | 2 | 43 |
|---|